Cite
HARVARD Citation
Doi, T. et al. (n.d.). Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet oncology. 18 (11), pp. 1512-1522. [Online].